17613943

pubmed:Citation

3

Since the brain neurotransmitter changes characterising panic disorder remain uncertain, we quantified brain noradrenaline and serotonin turnover in patients with panic disorder, in the absence of a panic attack. Thirty-four untreated patients with panic disorder and 24 matched healthy volunteers were studied. A novel method utilising internal jugular venous sampling, with thermodilution measurement of jugular blood flow, was used to directly quantify brain monoamine turnover, by measuring the overflow of noradrenaline and serotonin metabolites from the brain. Radiographic depiction of brain venous sinuses allowed differential venous sampling from cortical and subcortical regions. The relation of brain serotonin turnover to serotonin transporter genotype and panic disorder severity were evaluated, and the influence of an SSRI drug, citalopram, on serotonin turnover investigated. Brain noradrenaline turnover in panic disorder patients was similar to that in healthy subjects. In contrast, brain serotonin turnover, estimated from jugular venous overflow of the metabolite, 5-hydroxyindole acetic acid, was increased approximately 4-fold in subcortical brain regions and in the cerebral cortex (P < 0.01). Serotonin turnover was highest in patients with the most severe disease, was unrelated to serotonin transporter genotype, and was reduced by citalopram (P < 0.01). Normal brain noradrenaline turnover in panic disorder patients argues against primary importance of the locus coeruleus in this condition. The marked increase in serotonin turnover, in the absence of a panic attack, possibly represents an important underlying neurotransmitter substrate for the disorder, although this point remains uncertain. Support for this interpretation comes from the direct relationship which existed between serotonin turnover and illness severity, and the finding that SSRI administration reduced serotonin turnover. Serotonin transporter genotyping suggested that increased whole brain serotonin turnover most likely derived not from impaired serotonin reuptake, but from increased firing in serotonergic midbrain raphe neurons projecting to both subcortical brain regions and the cerebral cortex.

eng

IM

MEDLINE

1025-3890

Print

NLM

295-304

pubmed-meshheading:17613943-Adult, pubmed-meshheading:17613943-Brain, pubmed-meshheading:17613943-Case-Control Studies, pubmed-meshheading:17613943-Catheterization, Central Venous, pubmed-meshheading:17613943-Catheterization, Peripheral, pubmed-meshheading:17613943-Cerebrovascular Circulation, pubmed-meshheading:17613943-Citalopram, pubmed-meshheading:17613943-Genotype, pubmed-meshheading:17613943-Humans, pubmed-meshheading:17613943-Hydroxyindoleacetic Acid, pubmed-meshheading:17613943-Methoxyhydroxyphenylglycol, pubmed-meshheading:17613943-Middle Aged, pubmed-meshheading:17613943-Norepinephrine, pubmed-meshheading:17613943-Panic Disorder, pubmed-meshheading:17613943-Research Design, pubmed-meshheading:17613943-Serotonin, pubmed-meshheading:17613943-Serotonin Plasma Membrane Transport Proteins, pubmed-meshheading:17613943-Serotonin Uptake Inhibitors, pubmed-meshheading:17613943-Severity of Illness Index, pubmed-meshheading:17613943-Tomography, Emission-Computed, Single-Photon

Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor.

Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't